Select to view the solutions available in your location.
Track orders, get results, manage personal information, and more.
Order tests, track orders, get results, and more.
Learn more about our innovative products and services that help detect cancer earlier and power smarter treatment decisions.
Find out how our scientific rigor, quality standards, and development of future tests make us a leader in cancer testing and treatment guidance.
How one revolutionary test could change the health of millions.
Learn all about Exact Sciences, including our purpose, the people who drive it, our history, and the impact we’ve made.
Several Exact Sciences initiatives address disparities in cancer outcomes among U.S. Latinos.
Explore stories, news, and events that highlight our innovation, technology, and people fighting cancer on all fronts.
As we announced Monday, data supporting Exact Sciences' stool DNA (sDNA) screening platform for colorectal cancer will be presented in three posters at the American College of Gastroenterology’s Annual Scientific Meeting (ACG 2015), taking place this week in Honolulu.
In addition to the details we shared in the release, you can view key charts and tables from the posters with a short summary below.
The first poster shows that a clinically significant proportion of initial Cologuard users, 42 percent, age 50-74, the primary target age for screening, reported no previous colorectal cancer screening, while 36 percent of users overall were similarly unscreened previously.
These data suggest that the availability of Cologuard as a screening option may help increase the number of patients who get screened.
In a second poster, researchers looked at the decrease in colorectal cancer incidence and colorectal cancer death with sDNA screening compared to colonoscopy at various intervals.
The study found that screening with Cologuard at three-year intervals could reduce colorectal cancer death by 67 percent.
In a third poster, a newly completed patient preference study, corroborating the finding of the two previously published preference studies, finds that screen-naïve patients, who intend to be screened within the next year, prefer colonoscopy (40 percent) and multi-target sDNA (35 percent) significantly more often than FOBT or FIT (9-10 percent) or flexile sigmoidoscopy (4 percent).
There was no significant preference difference between colonoscopy and multi-target sDNA, but the difference between colonoscopy and multi-target sDNA compared to the other three tests was significant.
For more information on the posters and ACG 2015, please read our press release.